Etoposide, mitoxantrone and prednisone, a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma

Haematologica

Volumn 85, Issue 8, 2000, Pages 814-819

  Doorduijn, J K ^a   Spruit, P H ^a   Van der Holt, B ^a   Van't Veer, M B ^a   Budel, L M ^a   Lowenberg, B ^a   Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Elderly; NHL; Relapse

Indexed keywords

ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE;

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; DRUG INDUCED DISEASE; DRUG TOLERABILITY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PROGNOSIS; RELAPSE; RISK FACTOR; SALVAGE THERAPY; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMAN; LACTATE DEHYDROGENASE; LIFE TABLES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGE; MITOXANTRONE; NEOPLASM PROTEINS; PREDNISONE; PROGNOSIS; SAFETY; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033827053     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
2. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
3. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
4. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
5. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy
6. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
7. International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury
8. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ARA-C and dexamethasone (DHAP)
9. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group
10. Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma
11. Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status
12. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma
13. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease
14. Mitoxantrone in refractory non-Hodgkin's lymphoma. A Southwest Oncology Group study
15. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation
16. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
17. Toxicity and response criteria of the Eastern Cooperative Oncology Group
18. A predictive model for aggressive non-Hodgkin's lymphoma
19. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant
20. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma
21. Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: A preliminary report
22. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma